Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01910012 · ClinicalTrials.gov registry record · Phase 2

PH 2 ADI-PEG 20 Acute Myeloid Leukemia

A Phase 2 study, sponsored by Polaris Group.

Completed
Registry status
Phase 2
Development phase
43
Enrollment target

NCT01910012: Completed Phase 2 study, sponsored by Polaris Group.

NCT01910012 is a Phase 2 study that has completed, run by Polaris Group. The registered enrollment target is 43 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01910012, a Phase 2 study, has completed, sponsored by Polaris Group.

COMPLETED
Registry status
Phase 2
Development phase
43 participants
Enrollment target

Study Summary

Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers that require arginine. In this study, the investigators will evaluate the response rate, as determined by the revised International Working Group recommendations.

Interventions

  • DRUG ADI-PEG 20

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2015-01-06
Est. Completion 2017-05-05
Phase Phase 2
Polaris Group

13 total trials

What the finished NCT01910012 record still lists

NCT01910012 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).

The record links to 0 conditions, and to 1 intervention - of which ADI-PEG 20 is the first listed.

NCT01910012 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01910012 about?

NCT01910012 is a clinical study titled "PH 2 ADI-PEG 20 Acute Myeloid Leukemia". Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers that require arginine. In this study, the investigators will evaluate the...

What is the current status of trial NCT01910012?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2015-01-06. Estimated completion is 2017-05-05.

What interventions are being tested in trial NCT01910012?

The interventions under investigation include: ADI-PEG 20 (DRUG).

Who is sponsoring clinical trial NCT01910012?

This trial is sponsored by Polaris Group, which has 13 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01910012's enrollment target sits among peer trials

43 1332nd of 2000 higher than 662 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03726359 · 43 participants · Phase 1

    Phase I Study of Fractionated Stereotactic Radiation Therapy

  • NCT03850418 · 43 participants · Phase 2

    Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

  • NCT04144023 · 43 participants · Phase 1

    A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

  • NCT04176718 · 43 participants · Phase 2

    Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01910012, the US trial registry maintained by the National Library of Medicine. NCT01910012 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.